TeresaFieldMD

Hematology • Tampa, FL

Assistant Professor, Oncologic Sciences, USF-Morsani

Join to view full profile

Dr. Field is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Field's full profile

Already have an account?

Office
12902 Usf Magnolia Dr
Tampa, FL 33612
Phone+1 813-979-7208

Fax+1 813-979-3071

Summary

Dr. Teresa Field is a hematologist in Tampa, FL. She received her medical degree from University of Wisconsin School of Medicine and Public Health and has been in practice 24 years. She is experienced in hematologic oncology, myelofibrosis, hematopoietic stem cell transplantation, multiple myeloma, and internal medicine.

Education & Training

University of Wisconsin Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1996 - 1998
University of Wisconsin Hospitals and ClinicsResidency, Internal Medicine, 1993 - 1996
University of Wisconsin School of Medicine & Public HealthClass of 1993

Certifications & Licensure

FL State Medical License 1998 - 2025
WI State Medical License 1997 - 2009
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Clinical Trials

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders Start of enrollment: 1996 May 01
Completed
Phase 2
Bone Marrow Transplant in Treating Patients With Hematologic Cancers Start of enrollment: 1993 Mar 01
Completed
Phase 2
Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
Terminated
Phase 2, Phase 3
Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX Start of enrollment: 2005 Sep 01
Completed
Not Applicable
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Start of enrollment: 2005 Aug 01
Completed
Phase 4
Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant Start of enrollment: 2008 Mar 01
Completed
Not Applicable
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
Completed
Phase 2
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease Start of enrollment: 2012 Nov 14
Completed
Phase 1, Phase 2
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease Start of enrollment: 2014 Oct 29
Completed
Phase 1
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis Start of enrollment: 2014 Mar 25
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

14 citations
Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.
Joseph Pidala, Jongphil Kim, Brian C. Betts, Melissa Alsina, Ernesto Ayala
Biology of Blood and Marrow Transplantation. 2015-06-01
23 citations
In vivo IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation.
Joseph Pidala, Francisca Beato, Jongphil Kim, Brian C. Betts, Heather S.L. Jim
Haematologica. 2017-12-14
17 citations
Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome
Taiga Nishihori, Janelle Perkins, Asmita Mishra, Rami S. Komrokji, Jongphil Kim
Biology of Blood and Marrow Transplantation. 2014-06-01